“…Despite a lower dose than in other trials, the primary endpoint, complete response plus nodal partial response, was increased in the group receiving oblimersen (16 versus 7%, p = 0.039). However, the overall response rate was similar when partial responders were included (79). For patients with refractory multiple myeloma, a randomized trial compared oblimersen (7 mg/kg/day) combined with high-dose dexamethasone with steroid treatment alone.…”